로딩 중…
지수 로딩 중…
Fate Therapeutics, Inc.
FATE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$2.50+2.04%
2026-08-03
Financials
Valuation Metrics
Fate Therapeutics, Inc.'s Market Cap is $291M. At end of 2025 it was $117M. Ranked #2964 of 3,112 in US market (top 95%), #1332 of 1,445 on NASDAQ (top 92%), #243 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $291M | US#2,964/3,112 Sec#243/269 |
| Revenue | $6M | US#2,934/3,112 Sec#187/269 |
| Net Income | $-130M | US—/3,112 Sec—/269 |
| Total Assets | $285M | US#2,912/3,112 Sec#220/269 |
| Net Assets | $180M | US#2,769/3,112 Sec#204/269 |
| Value | ||
| P/B | 1.62x | US#928/3,112 Sec#44/269 |
| P/S | 46.14x | US#2,872/3,112 Sec#166/269 |
| FCF Yield | -37.09% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -72.29% | US#2,810/3,112 Sec#203/269 |
| ROA | -45.59% | US#2,950/3,112 Sec#205/269 |
| Op. Margin | -2207.47% | US#2,936/3,112 Sec#183/269 |
| Revenue Growth | -20.26% | US#2,779/3,112 Sec#152/269 |
| Financial Health | ||
| Debt Ratio | 58.54% | US#659/3,112 Sec#148/269 |
| Total Debt | $77M | US#2,445/3,112 Sec#130/269 |
| FCF | $-108M | US#2,602/3,112 Sec#156/269 |
| Cash | $40M | US#2,670/3,112 Sec#238/269 |
| Current Ratio | 5.85x | US#411/3,112 Sec#130/269 |
| Performance | ||
| 1Y Return | 133.64% | US#184/3,112 Sec#57/269 |
| 1M Return | -14.38% | US#2,790/3,112 Sec#199/269 |
| From 52W High | -22.60% | US#1,838/3,112 Sec#121/269 |
| 1Y MDD | -44.83% | US#2,203/3,112 Sec#167/269 |
| Trading | ||
| Volume | 1,250,945 shares | US#1,288/3,112 Sec#126/269 |
| Trading Value | $3M | US#2,811/3,112 Sec#232/269 |
| Per Share | ||
| EPS | $-1.15 | US—/3,112 Sec—/269 |
| BPS | $1.74 | US#2,540/3,112 Sec#183/269 |